Monoclonal antibodies for immunosuppression. by Waldmann, H, Hale, G, Clark, M, Cobbold, S, Benjamin, R, Friend, P, Bindon, C, Dyer, M, Qin, S, Bruggemann, M

THE USE OF MONOCLONAL ANTILYMPHOCYTE ANTIBODIES IN CLINICAL IMMUNOSUPPRESSION by Friend, P, Calne, R, White, D, Hale, G, Waldmann, H

Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. by Muthusamy, A, Vaidya, A, Sinha, S, Roy, D, Elker, D, Friend, P

“…The impact of alemtuzumab induction immunosuppression in pancreas transplantation was evaluated, with particular reference to steroid avoidance in maintenance. …”

Steroid-free immunosuppression in pancreas transplantation using Alemtuzumab induction by Muthusamy, A, Roy, D, Elker, D, Quiroga, I, Lale, R, Smith, J, Sujendran, V, Sinha, S, Vaidya, A, Friend, P

Impact of immunosuppression on the incidence of early subclinical renal allograft rejection: implications for protocol biopsy policy. by Roberts, I, Stratopoulos, C, Zilvetti, M, Reddy, S, Friend, P

“…In order to determine the impact of immunosuppression (IS) on the incidence of early subclinical rejection (SCR), we studied two groups of patients receiving different immunosuppressive regimens. …”

Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy. by Hester, J, Mills, N, Shankar, S, Carvalho-Gaspar, M, Friend, P, Wood, K

“…BACKGROUND: Leukocyte depletion at the time of transplantation with alemtuzumab (Campath-1H) has been demonstrated to be a potential strategy for reducing long-term exposure to immunosuppressive drugs. Although the impact of alemtuzumab treatment on the immune system has been explored, the effects of long-term immunosuppressive therapy in alemtuzumab-treated patients still need to be elucidated. …”

Reduction in subclinical renal allograft rejection with new immunosuppressive regimens: Evidence from early protocol biopsies by Roberts, I, Stratopoulos, C, Zilvetti, M, Reddy, S, Russell, C, Davies, DR, Friend, P

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. by Flechner, S, Friend, P, Brockmann, J, Ismail, H, Zilvetti, M, Goldfarb, D, Modlin, C, Mastroianni, B, Savas, K, Devaney, A, Simmonds, M, Cook, D

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation. by Hale, G, Waldmann, H, Friend, P, Calne, R

Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. by Trzonkowski, P, Zilvetti, M, Chapman, S, Wieckiewicz, J, Sutherland, A, Friend, P, Wood, K

“…Alemtuzumab (CAMPATH-1H) is a depleting agent introduced recently in transplantation and often used with reduced maintenance immunosuppression. In the current study we investigated the immune response of 13 kidney allograft recipients treated with alemtuzumab followed by weaned immunosuppression with reduced dose of mycophenolate mofetil (MMF) and tacrolimus. …”

Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. by Trzonkowski, P, Zilvetti, M, Friend, P, Wood, K

“…The impact of immunosuppressive drugs on leukocytes that escape depletion was also evaluated in vitro. …”

Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. by Trzonkowski, P, Zilvetti, M, Friend, P, Wood, K

“…The impact of immunosuppressive drugs on leukocytes that escape depletion was also evaluated in vitro. …”

Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts. by Cozzi, E, Vial, C, Ostlie, D, Farah, B, Chavez, G, Smith, K, Bradley, JR, Thiru, S, Davies, H, Wallwork, J, White, D, Goddard, M, Friend, P

“…To date, the best results in life-supporting pig-to-primate renal xenotransplantation have been obtained in recipients exposed to long-term immunosuppression with cyclophosphamide. As this agent is frequently associated with side-effects, we have explored the potential of a mycophenolate sodium-based maintenance immunosuppression in this model. …”

Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients by Brook, MO, Hester, J, Petchey, W, Rombach, I, Dutton, S, Bottomley, MJ, Black, J, Abdul-Wahab, S, Bushell, A, Lombardi, G, Wood, K, Friend, P, Harden, P, Issa, F

“…Control participants will receive a standard basiliximab-based immunosuppression regimen with long-term tacrolimus and mycophenolate mofetil immunosuppression. …”

Feasibility, long‐term safety and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients by Harden, PN, Game, D, Sawitzki, B, Van der Net, J, Hester, J, Bushell, A, Issa, F, Brook, MO, Alzhrani, A, Schlickeiser, S, Scotta, C, Petchey, W, Blancho, G, Tang, Q, Markmann, J, Lechler, RI, Roberts, IR, Friend, P, Hilton, R, Geissler, EK, Wood, KJ, Lombardi, G

“…Short‐term outcomes in kidney transplantation are marred by progressive transplant failure and mortality secondary to immunosuppression toxicity. Immune modulation with autologous polyclonal regulatory T cell (Treg) therapy may facilitate immunosuppression reduction promoting better long‐term clinical outcomes. …”

Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials by Sawitzki, B, Harden, PN, Reinke, P, Roberts, ISD, Hester, J, van der Net, JB, Petchey, W, Issa, F, Morris, PJ, Bushell, A, Friend, P, Wood, K, Geissler, EK, Et al.

“…<p><strong>Background:</strong>&nbsp;Use of cell-based medicinal products (CBMPs) represents a state-of-the-art approach for reducing general immunosuppression in organ transplantation. We tested multiple regulatory CBMPs in kidney transplant trials to establish the safety of regulatory CBMPs when combined with reduced immunosuppressive treatment.…”

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. by Watson, C, Bradley, J, Friend, P, Firth, J, Taylor, C, Bradley, JR, Smith, K, Thiru, S, Jamieson, N, Hale, G, Waldmann, H, Calne, R

“…They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. …”

Pancreas transplantation by Knight, S, Vogel, T, Friend, P

“…Meticulous organ retrieval technique and back-table preparation, and a standard implantation technique using enteric drainage are central to good outcomes. Modern immunosuppression has reduced acute rejection rates and lowered the need for long-term corticosteroids. …”

Risk analysis for deterioration of renal function after pancreas alone transplant. by Chatzizacharias, N, Vaidya, A, Sinha, S, Sharples, E, Smith, R, Jones, G, Brockmann, J, Friend, P

“…Our data suggest that PTA is a justifiable therapy for patients with hypoglycemia unawareness or other life-threatening diabetic complications, even in those with borderline renal function, provided that they do not suffer from severe proteinuria and appropriate monitoring and tailoring of immunosuppression is ensured.…”

Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial. by Friend, P, Hale, G, Waldmann, H, Gore, S, Thiru, S, Joysey, V, Evans, D, Calne, R

“…However, patients who received this additional immunosuppression experienced a significantly higher incidence of serious infections than controls, this negating any benefit from the treatment in terms of graft survival. …”